Eris Lifesciences Limited (ERIS)
as attached
Q1FY27 results (unaudited):
Standalone:
Revenue 444.0bn +(-23%) y-y (578.6bn)
PAT 48.3bn +(-52%) y-y (100.0bn)
Consolidated:
Revenue 873.3bn +13% y-y (773.0bn)
PAT 143.3bn +15% y-y (125.1bn)
Dividend: Rs 7.21/share (interim for FY27)
Commentary: Board approved re-appointment of M/s Kiran J. Mehta & Co. as Cost Auditors for FY27.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ERIS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ERIS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Eris Lifesciences Limited
Important.
The summary above is generated automatically from Eris Lifesciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.